Welcome to our dedicated page for Arrowhead Research news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Research stock.
Arrowhead Pharmaceuticals develops and commercializes RNA interference medicines that silence genes associated with intractable diseases. The company’s TRiM™ platform is used to design targeted RNAi therapeutics for tissues including liver, lung, muscle, adipose and central nervous system tissue.
Recurring ARWR news covers REDEMPLO® (plozasiran), an siRNA medicine approved in the United States and Australia as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. Company updates also address plozasiran data across hypertriglyceridemia, regulatory actions in additional geographies, pricing and market-access strategy, fiscal results, investor events, and clinical or partnering developments involving programs such as ARO-PNPLA3, ARO-INHBE and ARO-ALK7.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced FDA approval of REDEMPLO (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). REDEMPLO is the first FDA‑approved siRNA medicine for FCS and is administered by subcutaneous injection once every three months. The approval is based on Phase 3 PALISADE results showing a median triglyceride change of -80% versus -17% for pooled placebo and a lower numerical incidence of acute pancreatitis. REDEMPLO will be available in the U.S. before the end of the year, and Arrowhead is launching a patient support program and advancing commercial capabilities as it becomes a commercial‑stage company.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on November 25, 2025 at 4:30 p.m. ET to discuss fiscal year 2025 results for the period ended September 30, 2025. Investors can access a live audio webcast on the Events and Presentations page in the Investors section of the Arrowhead website. A replay will be available approximately two hours after the call ends. Analysts who wish to join the conference call must register in advance to receive a dial-in number and personalized PIN.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced participation in multiple November 2025 scientific and investor events. Key appearances include the AHA Scientific Sessions (Nov 7-10) with a moderated poster on zodasiran on Nov 10, 2:34 pm CST, multiple presentations at AASLD Liver Meeting (Nov 7-11) on fazirsiran data and imaging analyses on Nov 9, 8:00 am EST, a Jefferies Global Healthcare fireside chat on Nov 19, and a TD Cowen virtual fireside on Nov 24. Webcast and materials will be posted on the company Events and Presentations investor page.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that its board approved inducement equity grants on October 24, 2025 for 84 new employees under NASDAQ Listing Rule 5635(c)(4).
The grants entitle the recipients, in aggregate, to receive up to 127,230 restricted stock units (RSUs). These awards are outside the company's stockholder-approved equity incentive plans and vest annually over a four-year period.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced closing of its global license and collaboration agreement with Novartis on October 21, 2025, following expiration of HSR waiting periods and customary conditions.
Under the deal Novartis received an exclusive worldwide license to develop ARO-SNCA, a preclinical program using Arrowhead’s TRiMTM platform for subcutaneous CNS delivery targeting alpha-synuclein for Parkinson’s disease and related synucleinopathies. Arrowhead will complete preclinical work to enable a clinical trial application (CTA), after which Novartis will assume sole control of development, manufacturing, medical affairs, and commercialization.
Financial terms include a $200 million upfront payment, up to $2 billion in development, regulatory, and sales milestones, and tiered royalties up to the low double digits.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) filed for regulatory clearance to start a Phase 1/2a study of ARO-DIMER-PA, the company's first dual‑functional RNAi candidate designed to silence PCSK9 and APOC3 simultaneously using the TRiMTM platform.
Preclinical data showed potent lowering of PCSK9 and APOC3 and reductions in non‑HDL, LDL‑C, and triglycerides in dyslipidemic nonhuman primates. Arrowhead submitted the trial application to New Zealand regulators and, pending clearance, plans a randomized, double‑blind, placebo‑controlled, dose‑escalation study in up to 78 adults with mixed hyperlipidemia, evaluating safety, PK/PD, and effects on LDL‑C and triglycerides. The company noted potential clinical insights in 2026 and referenced an upcoming November 18, 2025 PDUFA date for plozasiran.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has filed a Complaint for Declaratory Judgment against Ionis Pharmaceuticals in the Delaware District Court regarding Ionis's patent (No. 9,593,333). The legal action seeks to declare Ionis's patent invalid and not infringed by Arrowhead's investigational drug plozasiran, which is currently under FDA review.
The dispute centers around plozasiran, a treatment for familial chylomicronemia (FCS), a severe rare disease causing extremely high triglyceride levels. Arrowhead's CEO Christopher Anzalone emphasized that the company developed plozasiran independently through its proprietary TRiM™ platform, without any contribution from Ionis. The company is seeking a declaratory decree rather than monetary relief.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted a regulatory clearance request to begin a Phase 1/2a clinical trial of ARO-MAPT, an RNAi therapeutic targeting Alzheimer's disease and other tauopathies. The investigational drug utilizes a novel proprietary delivery system that has shown promising results in preclinical studies, achieving blood-brain-barrier penetration and CNS target gene knockdown through subcutaneous administration.
The planned study will evaluate ARO-MAPT in up to 112 participants, including both healthy subjects and those with early Alzheimer's disease. The trial design includes multiple dosing schedules, with subjects receiving either one or three weekly doses, followed by monthly doses. Preclinical data presented at the RNA Leaders USA Congress 2025 demonstrated potent MAPT mRNA and Tau protein suppression throughout the CNS, suggesting potential for monthly or quarterly dosing regimens.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has entered into a significant global licensing and collaboration agreement with Novartis for ARO-SNCA, a preclinical stage siRNA therapy targeting Parkinson's Disease and other synucleinopathies.
The deal includes an upfront payment of $200 million to Arrowhead, with potential milestone payments of up to $2 billion plus tiered royalties reaching low double digits. The agreement centers on Arrowhead's proprietary TRiM™ platform, which has shown promising preclinical results in CNS delivery through subcutaneous administration.
Under the agreement, Arrowhead will complete preclinical research for CTA filing, after which Novartis will take control of development, manufacturing, and commercialization. The transaction is expected to close in H2 2025, subject to regulatory approvals.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in seven major conferences during September 2025. The company will present clinical data at the European Society of Cardiology (ESC) Congress, including results from the PALISADE study on Plozasiran for FCS patients and ARCHES-2 study on Zodasiran for mixed hyperlipidemia.
Additionally, Arrowhead will participate in several investor conferences, including Citi's Biopharma Back to School Conference, Cantor Global Healthcare Conference, H.C. Wainwright Global Investment Conference, and Morgan Stanley Global Healthcare Conference. The company will also present research on RNAi therapeutics for neurodegenerative diseases at the RNA Leaders USA Congress.